Blue

Tokens Fueling Innovation in the Dynamic Fantom DeFi Ecosystem

Source Node:
Time Stamp: January 11, 2024 11:52 AM - Modified On: January 11, 2024 - Published By:
Source Cluster:
Republished By Plato

In the rapidly evolving realm of Defi and L1’s, the Fantom ecosystem shines as a vibrant hub for innovation. Within this dynamic landscape, various protocols play pivotal roles in sculpting the future of decentralized finance on Fantom. Each protocol brings its distinct features, vision, and potential to the forefront, propelling growth, stability, and inclusivity within the Fantom DeFi ecosystem. The most known protocol in Fantom is SpookySwap (Ticker : BOO), an EVM-compatible DEX, has been pioneered since its April 2021 launch. Endorsed by the Fantom Foundation and bolstered by community

Bracket Labs Announces $2 Million Pre-Seed Raise to Support the Launch of its ‘Passages’ Trading Platform

Source Node:
Time Stamp: January 4, 2024 2:04 PM - Modified On: January 4, 2024 - Published By:
Source Cluster:
Republished By Plato

PANAMA CITY FLA – January 4, 2024 – Bracket Labs completed a $2 million pre-seed fundraise round to support the launch of "Passage," a volatility trading product available on the project’s BracketX trading platform. The debut of the range-bound product makes trading long and short volatility entirely on-chain easy for traders of all levels. In June 2023, Bracket Labs completed Binance Labs’ Season 5 Incubation Program and received investment from Binance Labs. In addition to completing the Incubation Program, Bracket Labs completed its pre-seed investment round from other notable crypto

Coya Therapeutics Reports Additional Biomarker and Imaging Data Showing Decrease in Neuroinflammation with COYA 301 in Alzheimer’s Disease.

Source Node:
Time Stamp: June 7, 2023 12:21 PM - Modified On: June 7, 2023 - Published By:
Source Cluster:
Republished By Plato

Highlights Coya reports new data illustrating that administration of COYA 301 (low dose Interleukin-2 (IL-2)) in an open- label study in 8 patients with mild to moderate AD (COYA 301 Trial) resulted in a statistically significant reduction in the expression of three well characterized proinflammatory cytokines -- Tumor Necrosis Factor alpha (TNF-α), Interleukin 6 (IL-6), and Interleukin 1- Beta (IL-1β) -- which correlated with lack of cognitive decline of the patients over the course of the study. TNF-α is one of the main inflammatory cytokines involved in initiating and propagating

Rock and Roll Hall of Famer Dave Mason to Join Sophia’s Mission as their National Spokesperson

Source Node:
Time Stamp: October 25, 2022 5:31 PM - Modified On: October 25, 2022 - Published By:
Source Cluster:
Republished By Plato

Dave Mason Spokesperson Announcements will be aired on Sophia’s Mission’s NEWHD Media Stations New York— 10/19/2022 — Father Zachary Martin, Founder of Sophia’s Mission and longtime friend of Dave Mason is proud to announce that beginning in November, Dave is joining his cause to serve as National Spokesperson. Sophia’s Mission is a registered 501©3 that advocates and creates meaningful employment for people living on the Autistic Spectrum and with Disabilities (ASD). Sophia’s Mission’s NEWHD Media, is making it possible for people with ASD and Disabilities to enter the exciting profession